Heart health check for prostate cancer patients on ARPI therapy
Part of Cancer, Kidney & urinary clinical trials.
This trial is for men with advanced prostate cancer who are taking ARPI therapy. It offers a special heart health consultation to help manage the increased heart risk that can come with these powerful cancer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced prostate cancer (very high-risk, lymph node positive, or stage IV).
- You are currently taking an ARPI medicine (like enzalutamide or apalutamide) and plan to stay on it for at least 18 months.
- You are either over 65 with at least one heart risk factor (like high blood pressure, high cholesterol, diabetes, family history of early heart disease, or calcium in heart arteries) OR you are 45 to 65 with at least two of those risk factors.
- You are able to care for yourself (ECOG score 0-2).
- You are not already seeing a cardio-oncology heart specialist.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a digital exercise program to see if it helps men with prostate cancer stay active while on hormone therapy. You may be able to join if you're starting or already on hormone therapy and also getting radiation therapy.
This study tests whether combining a time-restricted eating plan, a heart-healthy diet, and a weight-loss medication (GLP-1 receptor agonist) can help improve heart health and weight in men with prostate cancer who are receiving hormone therapy. It aims to reduce the risk of heart problems caused by hormone treatment.
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
This study looks at how a special CT heart scan (CCTA) can help manage heart disease risk in men with prostate cancer who are taking hormone therapy (ADT). It may help your care team better assess heart risk, especially if you also have other heart risk factors but no current heart symptoms.
This study tests whether a team of doctors, nurses, and other specialists can help reduce the risk of heart problems in men with prostate cancer who are on hormone therapy (ADT). It focuses on providing extra support for heart health.
This study checks how men starting hormone therapy (ADT) for prostate cancer are doing with their heart health. It offers follow-up visits at the cancer center to track blood pressure and lab results, with the goal of catching any heart-related issues early.
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.